Recombinant Erythropoietin for Chemotherapy-Related Anaemia
| Autor: | Andrew Briggs, Mark Sculpher, Diego F Ossa, Warren Cowell, Tim Littlewood, Emma McIntosh |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Blood transfusion Adolescent Drug-Related Side Effects and Adverse Reactions Anemia Cost-Benefit Analysis medicine.medical_treatment Lower risk Health administration Quality of life Surveys and Questionnaires Internal medicine Humans Medicine Erythropoietin Aged Pharmacology business.industry Health Policy Public Health Environmental and Occupational Health Middle Aged medicine.disease Recombinant Proteins United Kingdom Surgery Quality-adjusted life year Standard error Quality of Life Female business medicine.drug |
| Zdroj: | PharmacoEconomics. 25:223-237 |
| ISSN: | 1170-7690 |
| DOI: | 10.2165/00019053-200725030-00005 |
| Popis: | To assess both the health-related quality of life (HR-QOL) and the economic value of erythropoietin treatment in chemotherapy-related anaemia using direct utility elicitation and discrete choice experiment (DCE) methods from a societal perspective in the UK.The time trade-off (TTO) method was employed to obtain utility values suitable for the calculation of QALYs for no, mild, moderate and severe anaemia. Health-state descriptions were developed using the Functional Assessment of Cancer Therapy - Anaemia (FACT-AN) subscale and the EQ-5D questionnaires, and were validated by clinical experts and patients. In addition, a DCE was implemented to elicit preferences for various anaemia treatment scenarios. The DCE analysis comprised important aspects of treatment identified from a literature review and by consultation with expert clinicians and cancer patients. The DCE included cost as an attribute in order to elicit willingness-to-pay (WTP) values (pound, 2004 values). The two methods were applied in the same cross-sectional sample of 110 lay people. Face-to-face interviews were conducted between February and March 2004.The mean utility scores were 0.86 (standard error [SE] 0.014) for the no-anaemia state, and 0.78 (SE 0.016), 0.61 (SE 0.020) and 0.48 (SE 0.020) for the mild, moderate and severe anaemia states, respectively. The DCE results revealed the following preferences as significant predictors of choice: higher level of relief from fatigue, lower duration of administration, subcutaneous/intravenous administration versus cannula injection, GP versus hospital location, lower risk of infection or allergic reactions and lower cost per month to the patient. Attribute levels were valued higher for recombinant erythropoietin than for blood transfusion; this is reflected in an incremental welfare value of 368 pounds (95% CI 318, 419).The results highlight a societal view that the severity of chemotherapy-related anaemia will significantly affect cancer patients' HR-QOL. The DCE survey shows that the public value favourably the attributes of treatment with recombinant erythropoietin, and indicates a likely patient preference for treatment with recombinant erythropoietin over blood transfusion. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink